Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Funding for malaria genome sequencing
An exciting international consortium of scientists and funding agencies has been formed during the past year to provide the funds and reagents required to sequence the P. falciparum genome, and to produce, annotate and publish these sequences. Expand
Comparative genomics of the neglected human malaria parasite Plasmodium vivax
The synteny and isochore structure of P. vivax chromosomes are described, and it is shown that the parasite resembles other malaria parasites in gene content and metabolic potential, but possesses novel gene families and potential alternative invasion pathways not recognized previously. Expand
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
There is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards. Expand
The Complexity of Protective Immunity Against Liver-Stage Malaria1 2
Investigation of mechanisms of protective immunity induced by immunization with different vaccine delivery systems in genetically distinct inbred strains, genetically modified mice, and outbred mice establishes that there is a marked diversity of T cell-dependent immune responses that mediate sterile protective immunity against liver-stage malaria. Expand
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.
- S. Hoffman, Lucy M L Goh, +14 authors T. Richie
- Medicine, Biology
- The Journal of infectious diseases
- 15 April 2002
These results expand published findings demonstrating that immunization by exposure to thousands of mosquitoes carrying radiation-attenuated Pf sporozoites is safe and well tolerated and elicits strain-transcendent protective immunity that persists for at least 42 weeks. Expand
Primaquine therapy for malaria.
This review supports a recommendation for a regimen of 0.5 mg/kg primaquine daily for 14 days, on the basis of superior efficacy and good tolerability and safety in nonpregnant persons without glucose-6-phosphate dehydrogenase deficiency. Expand
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
To assess the potential treatment efficacy of convalescent plasma in reducing mortality in current patients with H5N1 influenza, a review of studies from the Spanish influenza era that used influenza-convalescent human blood products to treat patients with Spanish influenza complicated by pneumonia was conducted. Expand
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue
- Sophie H. Adjalley, G. Johnston, +8 authors D. Fidock
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 31 October 2011
Activity of the first-line antimalarial dihydroartemisinin and the partner drugs lumefantrine and pyronaridine against early gametocyte stages, along with moderate inhibition of mature gametocytes transmission to Anopheles mosquitoes are revealed. Expand
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia.
- J. Baird, H. Basri, +4 authors S. Hoffman
- The American journal of tropical medicine and…
- 1 May 1991
The weekly 300 mg base tablet of chloroquine, which has been the standard for prophylaxis against malaria for more than 40 years, was not effective against P. vivax in Arso PIR, Irian Jaya. Expand
Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay
The results indicated that PfHRP-2 antigen was not detectable in blood 6 days after initiation of curative chemotherapy, and suggest that such circulating antigens rarely lead to false-positive tests. Expand